share_log

Don't Ignore The Insider Selling In Guanze Medical Information Industry (Holding)

Don't Ignore The Insider Selling In Guanze Medical Information Industry (Holding)

不要忽視guanze medical信息行業板塊內部賣出的情況
Simply Wall St ·  10/04 06:17

Anyone interested in Guanze Medical Information Industry (Holding) Co., Ltd. (HKG:2427) should probably be aware that the CEO & Chairman, Xianzhen Meng, recently divested HK$1.0m worth of shares in the company, at an average price of HK$0.54 each. However, the silver lining is that the sale only reduced their total holding by 0.3%, so we're hesitant to read anything much into it, on its own.

任何對於guanze medical信息行業(控股)有興趣的投資者(HKG:2427)應該注意到,首席執行官兼董事長孟顯鎮最近以每股HK$0.54的均價脫手了價值100萬港元的公司股份。然而,一絲希望的是,這次賣出僅令他們的持股總量減少了0.3%,所以我們對此並不敢輕易斷定。

Guanze Medical Information Industry (Holding) Insider Transactions Over The Last Year

過去一年間的醫療信息行業(控股)內部交易

In fact, the recent sale by Xianzhen Meng was the biggest sale of Guanze Medical Information Industry (Holding) shares made by an insider individual in the last twelve months, according to our records. So what is clear is that an insider saw fit to sell at around the current price of HK$0.51. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. We note that this sale took place at around the current price, so it isn't a major concern, though it's hardly a good sign.

事實上,根據我們的記錄,孟顯鎮最近的賣出是過去十二個月內醫療信息行業(控股)內部個人進行的最大一筆交易。因此,明顯的是,內部人員認爲在HK$0.51左右的當前價格賣出是合適的。雖然內部人員的拋售是一個負面因素,但對我們來說,如果股票以較低價格出售則更爲負面。我們注意到這次交易是在當前價格附近進行的,所以這並不是一個重大關注點,儘管這並不是一個好跡象。

Xianzhen Meng sold a total of 1.92m shares over the year at an average price of CN¥0.54. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

孟顯鎮在過去一年內以人民幣0.54的均價賣出了192萬股。您可以在以下看到公司和個人過去12個月內的內部交易的圖表視覺展示。點擊下面的圖表,您可以看到每筆內部交易的詳細信息!

big
SEHK:2427 Insider Trading Volume October 3rd 2024
SEHK:2427 內幕交易量 2024年10月3日

I will like Guanze Medical Information Industry (Holding) better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying.

如果我看到一些大額內部買入交易,我會更喜歡觀澤醫療信息行業(控股)公司。在等待時,可以查看這份包含近期大量內部買入的被低估和小盤股的免費名單。

Insider Ownership

內部人員持股情況

Many investors like to check how much of a company is owned by insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Guanze Medical Information Industry (Holding) insiders own about HK$363m worth of shares (which is 75% of the company). This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.

許多投資者喜歡查看公司內部人員持有多少股份。通常,內部人員持有股份越高,內部人員就越有動力長期發展公司。觀澤醫療信息行業(控股)公司內部人員持有價值36300萬港元的股份(佔公司股份的75%)。這種內部人員持有大量股份通常會增加公司爲所有股東利益運行的機會。

So What Do The Guanze Medical Information Industry (Holding) Insider Transactions Indicate?

那麼,觀澤醫療信息行業(控股)公司內部交易顯示出什麼?

An insider hasn't bought Guanze Medical Information Industry (Holding) stock in the last three months, but there was some selling. And even if we look at the last year, we didn't see any purchases. It is good to see high insider ownership, but the insider selling leaves us cautious. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. To that end, you should learn about the 5 warning signs we've spotted with Guanze Medical Information Industry (Holding) (including 3 which make us uncomfortable).

過去三個月內沒有內部人員購買過觀澤醫療信息行業(控股)公司的股票,但有一些賣出。即使我們回顧過去一年,也沒有看到任何購買情況。看到內部人員持股較高是好事,但內部人員的賣出讓我們謹慎。因此,這些內部交易可以幫助我們建立關於股票的論點,但了解這家公司面臨的風險也很重要。爲此,您應該了解我們發現的觀澤醫療信息行業(控股)公司的5個警示信號(包括讓我們感到不舒服的3個)。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

當然,您可能會在其他地方找到一項出色的投資。因此,請查看此免費的有趣公司列表。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

對於本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論